TapewireFind a company

person · Reporting owner

Hadas Nicole R.

Disclosed activity across 1 company

Tapewire entity
91066
SEC CIK
0001602396

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Akebia Therapeutics, Inc.AKBA · Entity 6105SVP, Chief Legal OfficerMay 13, 2024May 14, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akebia Therapeutics, Inc.

Report date May 13, 2024 · Filed May 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect651,243 Reported balance After 2024-05-13 transaction · row 1
1 source row

Row 1 · 2024-05-13 · Sale · Disposed 12,016 · Balance 651,243

F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.

F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.

F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 13, 2024 Filed May 14, 2024 20:05 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 12,016 $1.26 $15,140.16
Disclosure

SEC source: 0001562180-24-004026 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 651,243

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.

F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:48 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 5,974 $1.58 $9,438.92
Disclosure

SEC source: 0001562180-24-002022 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 663,259

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:03 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 7,411 $1.52 $11,264.72
Disclosure

SEC source: 0001562180-24-001995 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 669,233

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.

F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantStock Option (Right to buy) · Derivative 224,000 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001562180-24-000973 · primarydocument.xml · derivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,000

Underlying: Common Stock · 224,000 shares

Expires 2034-01-31

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 149,300 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-000973 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 676,644

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Read SEC document
May 25, 2023 Filed May 26, 2023 01:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 63,186 $1.22 $77,270.16
Disclosure

SEC source: 0001562180-23-004504 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 524,344

F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.

Read SEC document
May 24, 2023 Filed May 26, 2023 01:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantEmployee Stock Option (Right to buy) · Derivative 200,000 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001562180-23-004504 · primarydocument.xml · derivative · entry 3

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-05-12

F3 · derivative.exercise_date: As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.

Read SEC document
May 24, 2023 Filed May 26, 2023 01:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-004504 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 587,530

F1 · shares: As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023

Read SEC document
May 12, 2023 Filed May 16, 2023 20:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-004169 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,530

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 13:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,088 $0.88 $954.72
Disclosure

SEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 3

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,530

F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 13:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,613 $0.88 $5,802.91
Disclosure

SEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,618

F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 13:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 5,333 $0.88 $4,679.71
Disclosure

SEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,231

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.

Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:05 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,677 $0.81 $5,429.74
Disclosure

SEC source: 0001562180-23-002037 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,564

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.

F2 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,078 $2.17 $2,340.01
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 5

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,241

F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.

F6 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2021 and 1,500 shares of the Issuers common stock purchased on December 31, 2021, each under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,556 $2.17 $14,231.11
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 4

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,319

F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,873 $2.17 $14,919.22
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 3

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 308,875

F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.

Read SEC document
February 28, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantEmployee Stock Option (Right to buy) · Derivative 200,000 $0.00 Strike: $2.16 $0.00
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · derivative · entry 6

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-02-28

F7 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Read SEC document
February 28, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,748

F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

Read SEC document
February 28, 2022 Filed Mar 3, 2022 02:10 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,555 $2.15 $14,124.71
Disclosure

SEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,748

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 00:33 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,060 $3.40 $3,604.00
Disclosure

SEC source: 0001562180-21-002542 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,303

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.

Read SEC document
March 16, 2021 Filed Mar 18, 2021 23:18 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 10,192 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-002356 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,363

F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:08 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 7,976 $3.40 $27,087.29
Disclosure

SEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 3

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,171

F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:08 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,309 $3.40 $21,425.99
Disclosure

SEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,147

F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.

Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:08 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantEmployee Stock Option (Right to buy) · Derivative 110,000 $0.00 Strike: $3.46 $0.00
Disclosure

SEC source: 0001562180-21-001785 · primarydocument.xml · derivative · entry 4

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2031-02-26

F5 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:08 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 62,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,456

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2020 and 1,200 shares of the Issuer's common stock purchased on December 31, 2020, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 00:28 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantStock Option (Right to buy) · Derivative 105,000 $0.00 Strike: $8.87 $0.00
Disclosure

SEC source: 0001562180-20-001936 · primarydocument.xml · derivative · entry 3

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2030-02-28

F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 00:28 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 7,050 $8.70 $61,335.00
Disclosure

SEC source: 0001562180-20-001936 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,756

F3 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 00:28 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 62,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-20-001936 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,806

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Read SEC document
April 11, 2019 Filed Apr 12, 2019 20:00 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 Disposition to issuerCommon Stock 11,929 $7.70 $91,853.30
Disclosure

SEC source: 0000899243-19-010589 · doc4.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,806

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

Read SEC document
February 28, 2019 Filed Mar 5, 2019 21:06 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantEmployee Stock Option (Right to buy) · Derivative 100,000 $0.00 Strike: $7.28 $0.00
Disclosure

SEC source: 0001562180-19-001676 · primarydocument.xml · derivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Read SEC document
February 28, 2019 Filed Mar 5, 2019 21:06 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 65,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-19-001676 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,735

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 451 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.

Read SEC document
December 12, 2018 Filed Dec 13, 2018 13:15 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 Tax withholdingCommon Stock 20,175 $8.94 $180,364.50
Disclosure

SEC source: 0000899243-18-030794 · doc4.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,284

F1 · balance_after: Includes 1,381 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018.

Read SEC document
February 28, 2018 Filed Mar 2, 2018 21:15 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantEmployee Stock Option (Right to buy) · Derivative 25,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001562180-18-001385 · primarydocument.xml · derivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Read SEC document
February 28, 2018 Filed Mar 2, 2018 21:15 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 17,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-18-001385 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,078

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date.

F2 · balance_after: The total amount of beneficial securities owned includes 774 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan.

Read SEC document
October 02, 2017 Filed Oct 4, 2017 20:21 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 6,250 $19.95 $124,687.50
Disclosure

SEC source: 0001562180-17-003206 · primarydocument.xml · nonDerivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,804

F2 · shares: Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2017.

Read SEC document
October 02, 2017 Filed Oct 4, 2017 20:21 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,553 $19.64 $30,500.92
Disclosure

SEC source: 0001562180-17-003206 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,054

F1 · shares: Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 restricted stock award.

Read SEC document
July 03, 2017 Filed Jul 6, 2017 16:24 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,554 $14.26 $22,156.47
Disclosure

SEC source: 0001562180-17-002434 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,607

F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.11 to $14.41, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

F3 · balance_after: The total amount of beneficial securities includes 1,305 shares of stock purchased on June 30, 2017 at $8.92 per share in connection with the Issuer's Employee Stock Purchase Plan.

Read SEC document
April 03, 2017 Filed Apr 4, 2017 20:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,556 $9.18 $14,280.19
Disclosure

SEC source: 0001562180-17-001429 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,856

F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.15 to $9.24, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
February 21, 2017 Filed Feb 23, 2017 21:02 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantStock Option (Right to buy) · Derivative 45,000 $10.14 Strike: $0.00 $456,300.00
Disclosure

SEC source: 0001562180-17-000880 · primarydocument.xml · derivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2027-02-21

F2 · derivative.exercise_date: 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Read SEC document
February 21, 2017 Filed Feb 23, 2017 21:02 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 GrantCommon Stock 28,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-17-000880 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,412

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date.

Read SEC document
January 01, 2017 Filed Jan 3, 2017 21:01 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,810 $10.49 $18,987.99
Disclosure

SEC source: 0001562180-17-000080 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,912

F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.

F2 · balance_after: The total amount of beneficial securities includes 807 shares of stock purchased on December 30, 2016 at $6.48 per share in connection with the Issuer's Employee Stock Purchase Plan.

Read SEC document
October 01, 2016 Filed Oct 4, 2016 20:12 UTC Akebia Therapeutics, Inc. AKBA · Entity 6105 SaleCommon Stock 1,556 $8.95 $13,933.67
Disclosure

SEC source: 0001562180-16-003206 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,915

F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through December 2, 2017.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.